Dalcetrapib is a new investigational drug that raises HDL without the detrimental blood pressure raising effect that led to the failure of an earlier drug in the same class (CETP Inhibitors).
A smaller and shorter test was performed while waiting for the larger, multi-year FDA trial to conclude and that trail revealed dalcetrapib produced a clinically significance REGRESSION of arterial plaque! Read more here.
Good things are on the horizon. I can't wait!
Next Discussion: whats your favorite fast food places to eat »